New hope for Hard-to-Treat cancers: targeted drug tested in chinese patients
NCT ID NCT04380753
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested the drug sotorasib (AMG 510) in 12 Chinese patients with advanced solid tumors that have a specific KRAS G12C mutation. The main goals were to check safety, how the drug moves through the body, and whether it shrinks tumors. All participants took the drug by mouth once daily.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AMG 510 (sotorasib)
- What this could lead to
- If successful, this could confirm that sotorasib is safe and effective for Chinese patients with KRAS G12C-mutated cancers, potentially expanding access to a targeted therapy.
- What could go wrong
- This is a very early (Phase 1) and small (12 participants) study focused on safety and dosing, not proof of benefit. Results may not generalize to larger populations, and side effects like liver or gastrointestinal issues are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS WITH KRAS P.G12C MUTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Prince of Wales Hospital
Shatin, New Territories, Hong Kong
-
University of Hong Kong, Queen Mary Hospital
Hong Kong, Hong Kong
-
Veterans General Hospital - Taichung
Taichung, 40705, Taiwan